Table 2.
Treatment characteristics of the study population (n = 52).
| Variable | Patients, n (%) |
|---|---|
| Nab-paclitaxel discontinuation: | |
| • Yes | 50 (96.2) |
| • No | 2 (3.8) |
| Reason for Nab-paclitaxel discontinuation: | |
| • Toxicity | 7 (14.0) |
| • Disease progression | 33 (66.0) |
| • Physician decision | 8 (16.0) |
| • Patient decision | 2 (4.0) |
| Atezolizumab discontinuation: | |
| • Yes | 45 (86.5) |
| • No | 7 (13.5) |
| Reason for atezolizumab discontinuation: | |
| • Toxicity | 6 (13.3) |
| • Disease progression | 36 (80.0) |
| • Physician decision | 1 (2.2) |
| • Patient decision | 2 (4.4) |
| Atezolizumab maintenance: | |
| • Yes | 8 (15.4) |
| • No | 44 (84.6) |